Recently, a phase I trial with prostate cancer-directed CAR T cells armored with a TGFβRDN to block TGF-β signaling was conducted illustrating both feasibility and importance of interfering with the TGF-β pathway (44). This evidence concerns the gene TGFB1 and prostate cancer.